Sanofi Pasteur will deliver the first of more than 65 million influenza vaccines to the United States throughout the 2016–2017 flu season.
Sanofi Pasteur, the vaccines division of Sanofi, announced on July 26, 2016 that the first doses of Fluzone (influenza vaccine) for the 2016–2017 flu season have been released by FDA for shipment. The company will deliver more than 65 million doses of the seasonal influenza vaccine to the United States throughout the year, Sanofi Pasteur said in a press announcement.
Sanofi’s Fluzone vaccine includes the Fluzone High-Dose vaccine, which is designed specifically for people 65 years of age and older; the Fluzone Quadrivalent vaccine, which protects against four influenza strains (two A strains and two B strains); and the Fluzone Intradermal Quadrivalent vaccine 2014 for adults 18 through 64 years of age. The Centers for Disease Control and Prevention (CDC) recommends annual influenza vaccination for everyone six months of age and older, with rare exception, and recommends receiving the vaccine as soon as it is available to help with prevention even before the season begins.
"There is general awareness of influenza among the public given its widespread prevalence," said David P. Greenberg, MD, associate vice-president and regional medical head North America, Sanofi Pasteur. "What is not well known is that influenza can be life-threatening and have a lasting health impact, especially for the most vulnerable populations. In the 2014–2015 season, the CDC estimated 40 million flu illnesses, 19 million flu-associated medical visits, and almost 1 million flu-associated hospitalizations."
Source: Sanofi Pasteur
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.